| Primary |
| Hyperphosphataemia |
42.7% |
| Product Used For Unknown Indication |
35.9% |
| Drug Use For Unknown Indication |
13.5% |
| Renal Failure Chronic |
1.3% |
| Hyperparathyroidism Secondary |
1.1% |
| Constipation |
1.1% |
| Hyperkalaemia |
0.7% |
| Hypertension |
0.6% |
| Fabry's Disease |
0.5% |
| Pain |
0.4% |
| Nephrogenic Anaemia |
0.3% |
| Anaemia |
0.3% |
| Vitamin D |
0.3% |
| Hypocalcaemia |
0.2% |
| Atrial Fibrillation |
0.2% |
| Back Pain |
0.2% |
| Blood Phosphorus Abnormal |
0.2% |
| Coronary Artery Disease |
0.2% |
| Essential Hypertension |
0.2% |
| Gout |
0.2% |
|
| Muscular Weakness |
19.7% |
| Death |
14.0% |
| Large Intestine Perforation |
6.3% |
| Intestinal Perforation |
6.0% |
| Vomiting |
6.0% |
| Gastrointestinal Haemorrhage |
5.4% |
| Intestinal Obstruction |
4.8% |
| Constipation |
4.1% |
| Sepsis |
3.8% |
| Melaena |
3.2% |
| Treatment Noncompliance |
3.2% |
| Cerebrovascular Accident |
2.9% |
| Myocardial Infarction |
2.9% |
| Peritonitis |
2.9% |
| Vascular Calcification |
2.9% |
| Abdominal Pain Upper |
2.5% |
| Diverticulitis |
2.5% |
| Hyperphosphataemia |
2.5% |
| Hypertension |
2.2% |
| Shock |
2.2% |
|
| Secondary |
| Hyperphosphataemia |
33.8% |
| Product Used For Unknown Indication |
30.4% |
| Drug Use For Unknown Indication |
18.4% |
| Constipation |
4.9% |
| Renal Failure Chronic |
2.8% |
| Hyperkalaemia |
1.8% |
| Hyperparathyroidism Secondary |
1.6% |
| Prophylaxis |
1.1% |
| Myocardial Ischaemia |
1.1% |
| Haemodialysis |
0.8% |
| Ill-defined Disorder |
0.7% |
| Essential Hypertension |
0.4% |
| Diabetic Neuropathy |
0.3% |
| Epilepsy |
0.3% |
| Vitamin D |
0.3% |
| Type 2 Diabetes Mellitus |
0.3% |
| Anaemia |
0.2% |
| Atrial Tachycardia |
0.2% |
| Chronic Myeloid Leukaemia |
0.2% |
| Coronary Artery Disease |
0.2% |
|
| Muscular Weakness |
13.7% |
| Shock |
12.0% |
| Large Intestine Perforation |
9.7% |
| Melaena |
9.7% |
| Vascular Calcification |
7.4% |
| Constipation |
4.6% |
| Hyperphosphataemia |
4.0% |
| Stillbirth |
4.0% |
| Diverticulitis |
3.4% |
| Intra-uterine Death |
3.4% |
| Vomiting |
3.4% |
| Weight Increased |
3.4% |
| Anaphylactic Reaction |
2.9% |
| Infectious Peritonitis |
2.9% |
| Neutropenia |
2.9% |
| Peritonitis |
2.9% |
| Sciatica |
2.9% |
| Anaemia |
2.3% |
| Gastrointestinal Perforation |
2.3% |
| Hypocholesterolaemia |
2.3% |
|
| Concomitant |
| Drug Use For Unknown Indication |
32.5% |
| Product Used For Unknown Indication |
30.5% |
| Nuclear Magnetic Resonance Imaging |
9.4% |
| Hypertension |
3.5% |
| Angiogram |
3.2% |
| Hyperparathyroidism Secondary |
2.7% |
| Peritoneal Dialysis |
2.3% |
| Hyperphosphataemia |
1.8% |
| Nuclear Magnetic Resonance Imaging Brain |
1.8% |
| Renal Failure Chronic |
1.7% |
| Dialysis |
1.5% |
| Pain |
1.5% |
| Prophylaxis |
1.2% |
| Anaemia |
1.2% |
| Imaging Procedure |
1.1% |
| Multiple Myeloma |
0.8% |
| Thrombosis Prophylaxis |
0.8% |
| Haemodialysis |
0.8% |
| Diabetes Mellitus |
0.7% |
| Nuclear Magnetic Resonance Imaging Abdominal |
0.7% |
|
| Vomiting |
23.1% |
| Skin Tightness |
10.9% |
| Nephrogenic Systemic Fibrosis |
7.2% |
| Therapeutic Response Decreased |
7.1% |
| Weight Decreased |
5.0% |
| Death |
4.6% |
| Skin Induration |
4.0% |
| Thrombocytopenia |
4.0% |
| Skin Ulcer |
3.5% |
| Sepsis |
3.4% |
| Peritonitis |
3.3% |
| Pyrexia |
3.1% |
| Tremor |
3.0% |
| Pain |
2.9% |
| Nausea |
2.8% |
| Renal Failure |
2.7% |
| Renal Failure Chronic |
2.7% |
| Peritonitis Bacterial |
2.6% |
| Unresponsive To Stimuli |
2.1% |
| Oedema Peripheral |
2.0% |
|
| Interacting |
| Product Used For Unknown Indication |
66.7% |
| Arthritis Fungal |
8.3% |
| Atrial Fibrillation |
8.3% |
| Hyperphosphataemia |
8.3% |
| Prophylaxis Against Gastrointestinal Ulcer |
4.2% |
| Renal Failure Chronic |
4.2% |
|
| Fungal Infection |
66.7% |
| Pericardial Haemorrhage |
33.3% |
|
